- Nanotechnology company Nanoveu (NVU) receives patent cooperation treaty approval for EyeFyx
- The patent secures intellectual property rights in multiple markets including Australia, Japan, Europe, China, the UK and the USA
- EyeFyx provides vision correction for screen images and helps people suffering from farsightedness view images and text on digital screens without glasses
- Nanoveu is now in the process of investigating opportunities to commercialise the technology
- Nanoveu closed 7.32 per cent in the red on Thursday, with shares trading at 3.8 cents each
Nanotechnology company Nanoveu (NVU) has received patent cooperation treaty approval for EyeFyx.
The patent secures intellectual property rights in multiple markets including Australia, Japan, Europe, China, the UK and the USA.
EyeFyx provides vision correction for screen images via a film that is printed with different nano-lens structures.
The technology uses nano-imprinting lithography (NIL) to produce a thin-film lens that can be applied to select digital devices.
It’s then combined with an embedded software that renders clear images onto the retina of a person with blurred vision.
With the use of EyeFyx, people suffering from presbyopia, or farsightedness, are able to view images and text on digital screens without reading glasses.
Presbyopia is the gradual loss of the eyes’ ability to focus on nearby objects.
It is a normal occurrence with ageing and typically become more noticeable in middle age and continues to deteriorate with age.
“We are very excited for Nanoveu to be granted patent cooperation treaty approval for EyeFyx, as it represents one of the next steps in the commercialisation process,” CEO Alfred Chong said.
“A significant market exists for EyeFyx and we now look forward to advancing commercial discussions with interested parties globally.”
Nanoveu is now in the process of investigating opportunities to commercialise the technology.
Nanoveu closed 7.32 per cent in the red on Thursday, with shares trading at 3.8 cents each.